Consensus Haemonetics Corporation

Stocks

HAE

US4050241003

Medical Equipment, Supplies & Distribution

Market Closed - NYSE 04:00:02 28/10/2026 HKT			5-day change	1st Jan Change
119.97 ^USD	+0.65%		+1.49%	+49.68%

10-20	Haemonetics Gets FDA Approval for Vascular Closure Device	DJ
10-20	Haemonetics says FDA clears vascular closure device	RE

Evolution of the Average Target: Haemonetics Corporation

Evolution of the Target Price: Haemonetics Corporation

Changes in Analyst Recommendations: Haemonetics Corporation

a253ca56501ec69c07c713f1.t_zJghsblDHHz2iBH3COxrfUdoHBeJntfr8kIkXfT1s._a37ryls4nOFrBz0SzW584WzDvK4K9raPYlIZSudKS2PlvraeGvTBPWLGw~f2cc5214a8410a172e62102f165df627

Analysts' recommendations: Haemonetics Corporation

10-09	Barrington Adjusts Price Target on Haemonetics to $140 From $118, Keeps Outperform Rating	MT
09-18	Haemonetics Shares Rise After Citigroup Upgrade	MT
09-17	Citigroup Upgrades Haemonetics to Buy From Neutral, Adjusts Price Target to $123 From $92	MT
08-19	Barrington Raises Price Target on Haemonetics to $118 From $95, Keeps Outperform Rating	MT
08-13	BofA Securities Adjusts Price Target on Haemonetics to $100 From $93	MT
08-12	BofA Securities Adjusts Haemonetics Price Target to $100 From $93	MT
08-07	Barrington Research Adjusts Haemonetics PT to $95 From $89, Maintains Outperform Rating	MT
05-22	Haemonetics Likely to See Upside as Core Businesses Improve, BofA Securities Says	MT
05-22	BofA Securities Upgrades Haemonetics to Buy From Neutral, Price Target is $80	MT
05-12	Barrington Cuts Price Target on Haemonetics to $89 From $94, Keeps Outperform Rating	MT
01-12	Barrington Adjusts Price Target on Haemonetics to $93 From $90, Maintains Outperform Rating	MT
12-15	Needham Downgrades Haemonetics to Hold From Buy, Removes $78 Price Target	MT
12-11	Citigroup Downgrades Haemonetics to Neutral From Buy, Adjusts PT to $88 From $77	MT
11-08	Haemonetics Taking Prudent View on Guidance After Plasma Recovery, BofA Says	MT
11-07	BofA Securities Upgrades Haemonetics to Neutral From Underperform, Raises Price Target to $75 From $58	MT
11-07	Needham Raises Price Target on Haemonetics to $78 From $68, Keeps Buy Rating	MT
12/08/25	Haemonetics Shares Fall After Raymond James Downgrade	MT
11/08/25	Raymond James Downgrades Haemonetics to Outperform From Strong Buy	MT
09/08/25	Haemonetics Shares Fall After JPMorgan Downgrade	MT
08/08/25	Needham Cuts Price Target on Haemonetics to $68 From $84, Keeps Buy Rating	MT
08/08/25	JPMorgan Downgrades Haemonetics to Neutral From Overweight, Adjusts Price Target to $62 From $85	MT
10/07/25	Haemonetics Shares Rise After Upgrade From Citigroup	MT
09/07/25	Citigroup Upgrades Haemonetics to Buy From Neutral, Lifts Price Target to $90 From $71	MT
09/07/25	Analyst recommendations: Illumina, Freeport-McMoran, XPO, T-Mobile US…
26/06/25	Baird Initiates Coverage on Haemonetics With Outperform Rating, $87 Price Target	MT

More recommendations

Other Medical Equipment, Supplies & Distribution

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	HAEMONETICS CORPORATION					+4.46%
	ABBOTT LABORATORIES					+13.01%
	STRYKER CORPORATION					+18.45%
	MEDTRONIC PLC					+10.37%
	ESSILORLUXOTTICA					+23.38%
	CENCORA, INC.					+11.84%
	HOYA CORPORATION					+17.29%
	BECTON, DICKINSON AND COMPANY					-0.42%
	IDEXX LABORATORIES, INC.					+22.41%
	ALCON INC.					+29.52%
	Average					+15.03%
	Weighted average by Cap.					+15.17%